Lanrenet

Lanreotide, the active ingredient in Lanrenet, is a somatostatin analog presented as a subcutaneous injection for subcutaneous use. It treats hormone‑related disorders such as acromegaly and certain neuroendocrine tumors in adult patients.

GNH USA supplies Lanrenet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lanrenet is a somatostatin analog used to manage conditions driven by excess hormone secretion.

Acromegaly: reduces excess growth hormone, helping control IGF‑1 levels and disease symptoms. Neuroendocrine tumors: inhibits hormone release that can cause tumor‑related flushing and diarrhea. Carcinoid syndrome: decreases serotonin and other vasoactive substances, alleviating flushing and abdominal cramps.

Lanrenet may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema - Nausea or abdominal discomfort - Diarrhea or constipation - Headache - Fatigue - Mild hyperglycemia

Serious or Rare Side Effects: - Gallbladder disease or biliary sludge - Severe hyperglycemia or new‑onset diabetes - Pancreatitis - Cardiac arrhythmias - Severe allergic reactions (anaphylaxis) - Acute pancreatitis

Before initiating therapy, consider the following precautions.

Assess baseline glucose levels: monitor for hyperglycemia, especially in diabetic patients. Evaluate gallbladder status: patients with gallstones may require monitoring for biliary complications. Screen for pancreatic disease: avoid use in active pancreatitis. Monitor cardiac function: observe for arrhythmias in patients with pre‑existing heart conditions. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanrenet may interact with other medications; awareness of interaction severity is important.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampicin) that may reduce lanreotide exposure. - Long‑acting octreotide formulations: concurrent use can increase risk of gallbladder disease.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide may affect glucose control, requiring dose adjustments. - Oral contraceptives: possible reduction in hormone levels, monitor efficacy. - Antiplatelet or anticoagulant drugs: increased risk of gastrointestinal bleeding.